Detail akcie Amphastar Pharmactc online

Business Summary: Amphastar Pharmaceuticals, Inc. is a biopharmaceutical company that focuses primarily on developing, manufacturing, marketing, and selling generic and proprietary injectable, inhalation, and intranasal products. Additionally, it sells insulin API products. Most of its finished products are used in hospital or urgent care clinical settings and are primarily contracted and distributed through group purchasing organizations and drug wholesalers. The Company manufactures and sells over 25 products, such as BAQSIMI (glucagon) nasal powder 3mg, Primatene MIST, Glucagon for Injection Emergency Kit, Enoxaparin, Naloxone and Other Marketed Products, including Cortrosyn (cosyntropin for injection), Amphadase, Epinephrine injection, Lidocaine jelly, Lidocaine topical solution, Phytonadione injection, and others. The Company manufactures and sells two API products, Recombinant Human Insulin (RHI API) and porcine insulin API, for the injectable insulin market.
Financial Summary: BRIEF: For the six months ended 30 June 2025, Amphastar Pharmaceuticals Inc revenues decreased 3% to $344.9M. Net income decreased 31% to $56.3M. Revenues reflect United States segment decrease of 5% to $329.6M, China segment decrease of 81% to $380K. Net income also reflects Other Nonoperating Income (Expense) decrease from $6.2M (income) to $723K (expense), Research and development increase of 44% to $15.9M (expense).